Xeris director granted RSUs and options
Xeris Biopharma Holdings director Brady James Aloysius received new equity awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Xeris Biopharma Holdings director Brady James Aloysius received new equity awards. He was granted 24,193 shares of common stock through restricted stock units under the 2018 Stock Option and Incentive Plan, bringing his direct holdings to 113,359 shares.
He was also granted stock options for 32,996 shares of common stock at an exercise price of $6.15 per share, expiring on June 4, 2036. Both the restricted stock units and options vest in full on the earlier of June 4, 2026 or the company’s next annual meeting of stockholders, subject to his continued service.
Insider Trade Summary
Grant/Award: 57,189 shares
Grant/Award
2 txns
Insider
Brady James Aloysius
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 32,996 | $6.15 | $203K |
| Grant/Award | Common Stock | 24,193 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 32,996 contracts (Direct);
Common Stock — 113,359 shares (Direct)
Footnotes (2)
- F1. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
- F2. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
Key Figures
RSU grant: 24,193 shares
Shares held after grant: 113,359 shares
Stock options granted: 32,996 options
+3 more
6 metrics
RSU grant
24,193 shares
Restricted stock units granted to director on June 4, 2026
Shares held after grant
113,359 shares
Total common stock directly held after RSU award
Stock options granted
32,996 options
Options on common stock granted on June 4, 2026
Option exercise price
$6.15 per share
Exercise price for 32,996 stock options
Option expiration
June 4, 2036
Expiration date of the granted stock options
Vesting trigger date
June 4, 2026
Awards vest on this date or at next annual meeting
Key Terms
restricted stock unit, 2018 Stock Option and Incentive Plan, stock options, vesting
4 terms
restricted stock unit financial
"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
2018 Stock Option and Incentive Plan financial
"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan"
stock options financial
"These stock options were acquired pursuant to a grant under the Plan."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
vesting financial
"These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Xeris Biopharma (XERS) report for Brady James Aloysius?
Xeris Biopharma reported that director Brady James Aloysius received equity compensation. He was granted 24,193 restricted stock units and stock options for 32,996 shares under the 2018 Stock Option and Incentive Plan as part of his service-related compensation package.
What are the key terms of the new Xeris Biopharma (XERS) stock options granted?
The new stock options cover 32,996 shares of Xeris Biopharma common stock at an exercise price of $6.15 per share. They expire on June 4, 2036 and were granted under the company’s 2018 Stock Option and Incentive Plan as equity compensation.
When do Brady James Aloysius’s new Xeris Biopharma (XERS) equity awards vest?
Both the restricted stock units and the stock options vest in full upon the earlier of June 4, 2026 or the date of Xeris Biopharma’s next annual meeting of stockholders, provided Brady James Aloysius continues his service with the company through the vesting date.
Are the new Xeris Biopharma (XERS) insider grants open-market purchases or compensation awards?
The reported grants are compensation awards, not open-market purchases. The common stock was acquired via restricted stock unit grants, and the stock options were granted under the 2018 Stock Option and Incentive Plan, both tied to continued service rather than market transactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates